Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International ...

Isomyosamine is a novel plant alkaloid small molecule that regulates the immuno-metabolic system by modulating pro-inflammatory cytokines, including TNF-alpha, which plays a role in inflammation ...

Led by AbbVie’s Humira, biologic TNF inhibitors transformed the treatment of autoimmune diseases over the past 20 years. However, the biologic modality can cause adverse effects and loss of ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

The AI and machine learning technology of Renova Health, which comprises natural language processing (NLP) and a large ...

Abbvie’s TNF inhibitor Humira (adalimumab ... including Janssen’s Remicade (infliximab) and Humira, which faced the introduction of biosimilars in Europe in 2018. “In 2019, biosimilars ...

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced ...

2001). Patients with ICH had high levels of excitatory and inflammatory molecules such as glutamate, interleukin-6, and tumor necrosis alpha. These findings suggested that inflammation and ...